Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

vs. 30.4%, p =0.07) and device related thrombosis (4.5% Both major (1.4% vs. 2.1%, p =0.72) and minor (27.8% vs. 19.4%, p =0.17) in-hospital complications were similar between the combined and control group, respectively. At 45 days, presence of peri-device leak (18.3% vs. 4.5%, p =0.96) on transesophageal echocardiogram did not differ.

Ablation 40

Ablation Arrhythmia Thrombosis Echocardiogram 40

DAIC

MARCH 8, 2024

However, there are shortcomings associated with LVAD implantation: complications include infection, blood clotting (thrombosis), stroke and bleeding. As an alternative therapeutic option, LVAD heart pumps have been implanted to help patients with end-stage heart failure sustain blood circulation in the body.

Blood Clot 98

Blood Clot Heart Failure Quality of Life Innovation 98

Journal of Cardiovascular Electrophysiology

DECEMBER 4, 2024

However, the presence of residual trabeculation did not contribute to PDL or device-related thrombosis at follow-up or affect the clinical outcomes. However, the PDL and device-related thrombosis at 45 days and 1 year were comparable between the two groups (37% vs. 23%, p =0.24; 28% vs. 31%, p =0.84; 2.1% vs. 1.4%, p =0.50; 6.9%

Thrombosis 40

Thrombosis Atrial Fibrillation Outcomes Research 40

Cardiology Update

APRIL 9, 2024

The primary non-inferiority endpoint was MACCE (a composite of cardiac death, MI, ischaemic stroke, stent thrombosis, or target vessel revascularisation). The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5).

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52